Endotoxin is one of 100 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
68 competitors in Metabolic Syndrome
Crestor
Actos
Glucophage
Avandia
Geodon
Ozempic
Bayer Aspirin
Trexall
Uloric
Victoza
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details